NANOVIRICIDES, INC. has filed an amendment to its prospectus, which allows the company to offer up to $2,374,774 in common stock. This move is significant as it indicates the company's ongoing efforts to raise capital to support its operations and research in the pharmaceutical preparations industry.

The filing, dated October 21, 2026, is an amendment to the prospectus supplement originally dated July 17, 2026, and further amended on July 27, 2026. The updated prospectus is part of an 'at the market offering' program with D. Boral Capital LLC, which serves as the sales agent for the offering.

Background

NANOVIRICIDES, INC. is a company incorporated in Delaware, classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. The company trades on the New York Stock Exchange under the ticker symbol NNVC. Its recent filings include a DEF 14A on October 8, 2026, and an 8-K on September 29, 2026.

What the Filing Says

The amendment states, "This Amendment is being filed in connection with our previously announced 'at the market offering' program, and to update the maximum amount of shares of our common stock... that we may issue and sell from time to time through or to D. Boral Capital LLC as sales agent or principal."

As of October 19, 2026, the aggregate market value of NANOVIRICIDES' common stock held by non-affiliates was approximately $43.16 million. The company has already sold about $12 million worth of shares in the past year, and the new amendment will allow for additional offerings up to the specified amount.

Impact

This update may affect current and potential investors, as the ability to raise additional capital could influence the company's growth trajectory and operational capabilities. The pharmaceutical preparations industry is characterized by ongoing research and development, and access to capital is crucial for companies like NANOVIRICIDES to advance their projects.

What's Next

The filing does not specify what happens next, but it indicates that if the company's public float increases, it may file additional amendments to the prospectus supplement to allow for further sales of common stock.

Source: SEC Accession Number 0001104659-26-117595